Adrenas Therapeutics
BridgeBio Pharma is a biopharmaceutical company dedicated to discovering, creating, testing, and delivering transformative medicines for patients suffering from genetic diseases. Founded in 2015, it focuses on well-characterized genetic diseases and develops therapies at their source, leveraging scientific advancements and a decentralized corporate model to accelerate the development and delivery of medicines globally.
Industries
Nr. of Employees
small (1-50)
Adrenas Therapeutics
Raleigh, North Carolina, United States, North America
Products
Oral transthyretin stabilizer for ATTR cardiomyopathy (approved therapy)
Orally administered small-molecule TTR stabilizer indicated to reduce cardiovascular death and cardiovascular-related hospitalization in adults with transthyretin-mediated cardiomyopathy.
cPMP substrate replacement therapy for MoCD Type A (regulatory submission-stage)
Cyclic pyranopterin monophosphate (cPMP) substrate replacement therapy developed to replace deficient substrate in molybdenum cofactor deficiency Type A and permit downstream enzyme activation.
Oral transthyretin stabilizer for ATTR cardiomyopathy (approved therapy)
Orally administered small-molecule TTR stabilizer indicated to reduce cardiovascular death and cardiovascular-related hospitalization in adults with transthyretin-mediated cardiomyopathy.
cPMP substrate replacement therapy for MoCD Type A (regulatory submission-stage)
Cyclic pyranopterin monophosphate (cPMP) substrate replacement therapy developed to replace deficient substrate in molybdenum cofactor deficiency Type A and permit downstream enzyme activation.
Services
Patient support and access program
Insurance navigation, financial assistance, and dedicated support services to assist patients in accessing therapies.
No-charge genetic testing and counseling program
Genetic testing and counseling service for eligible patients to detect variants in disease-associated genes to support diagnosis and study recruitment.
Patient support and access program
Insurance navigation, financial assistance, and dedicated support services to assist patients in accessing therapies.
No-charge genetic testing and counseling program
Genetic testing and counseling service for eligible patients to detect variants in disease-associated genes to support diagnosis and study recruitment.
Expertise Areas
- Clinical trial management
- Gene therapy development
- Small-molecule drug discovery
- CMC and commercial manufacturing oversight
Key Technologies
- AAV9-based systemic gene therapy
- Small-molecule negative allosteric modulators (GPCR antagonists)
- Substrate replacement therapy chemistry
- Biomarker assays for urine/CSF/brain metabolites (e.g., NAA)